{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:01:47Z","timestamp":1762761707160,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbrc.2020.08.050","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T02:58:25Z","timestamp":1598583505000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Methotrexate, a small molecular scaffold targeting Kv1.3 channel extracellular pore region"],"prefix":"10.1016","volume":"532","author":[{"given":"Zili","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weishan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.08.050_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180762","article-title":"Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial","volume":"12","author":"Tarcha","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.08.050_bib2","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"Beeton","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.08.050_bib3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1124\/mol.104.008193","article-title":"Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases","volume":"67","author":"Beeton","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12576-014-0331-x","article-title":"Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease","volume":"65","author":"Kazama","year":"2015","journal-title":"J.\u00a0Physiol. Sci."},{"key":"10.1016\/j.bbrc.2020.08.050_bib5","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1096\/fj.14-251967","article-title":"Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases","volume":"28","author":"Chhabra","year":"2014","journal-title":"Faseb. J."},{"key":"10.1016\/j.bbrc.2020.08.050_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.imbio.2012.05.013","article-title":"The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis","volume":"218","author":"Toldi","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.bbrc.2020.08.050_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2014.07.003","article-title":"Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model","volume":"55","author":"Kundu-Raychaudhuri","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.bbrc.2020.08.050_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/toxins8040115","article-title":"The scorpion toxin analogue BmKTX-D33H as a potential Kv1.3 channel-selective immunomodulator for autoimmune diseases","volume":"8","author":"Ye","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.bbrc.2020.08.050_bib9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/acs.molpharmaceut.5b00023","article-title":"In silico identification of PAP-1 binding sites in the Kv1.2 potassium channel","volume":"12","author":"Jorgensen","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbrc.2020.08.050_bib10","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/leu.2013.56","article-title":"Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia","volume":"27","author":"Leanza","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2020.08.050_bib11","doi-asserted-by":"crossref","first-page":"105776","DOI":"10.1016\/j.intimp.2019.105776","article-title":"PAP-1 ameliorates DSS-induced colitis with involvement of NLRP3 inflammasome pathway","volume":"75","author":"Mei","year":"2019","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.bbrc.2020.08.050_bib12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/mol.105.015669","article-title":"Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases","volume":"68","author":"Schmitz","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1152\/jn.00154.2009","article-title":"Novel potassium channel blocker, 4-AP-3-MeOH, inhibits fast potassium channels and restores axonal conduction in injured Guinea pig spinal cord white matter","volume":"103","author":"Sun","year":"2010","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/md13010529","article-title":"Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK","volume":"13","author":"Pennington","year":"2015","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bbrc.2020.08.050_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14712598.2017.1346606","article-title":"Treating autoimmune disorders with venom-derived peptides","volume":"17","author":"Shen","year":"2017","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.bbrc.2020.08.050_bib16","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1038\/srep09881","article-title":"Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2020.08.050_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2014.03.101","article-title":"Unusual binding mode of scorpion toxin BmKTX onto potassium channels relies on its distribution of acidic residues","volume":"447","author":"Chen","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2020.08.050_bib18","doi-asserted-by":"crossref","first-page":"19058","DOI":"10.1074\/jbc.M802054200","article-title":"Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease","volume":"283","author":"Han","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.08.050_bib19","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1021\/ci700178w","article-title":"Molecular mechanism of the sea anemone toxin ShK recognizing the Kv1.3 channel explored by docking and molecular dynamic simulations","volume":"47","author":"Jin","year":"2007","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.bbrc.2020.08.050_bib20","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1021\/pr800494a","article-title":"Different residues in channel turret determining the selectivity of ADWX-1 inhibitor peptide between Kv1.1 and Kv1.3 channels","volume":"7","author":"Yin","year":"2008","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.bbrc.2020.08.050_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/17512433.2015.1077698","article-title":"Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis","volume":"8","author":"Subesinghe","year":"2015","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jmr.1037","article-title":"Selectively weakened binding of methotrexate by human dihydrofolate reductase allows rapid ex\u00a0vivo selection of mammalian cells","volume":"24","author":"Volpato","year":"2011","journal-title":"J.\u00a0Mol. Recogn."},{"key":"10.1016\/j.bbrc.2020.08.050_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00594","article-title":"Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K(+) channel","volume":"2","author":"Banerjee","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.bbrc.2020.08.050_bib25","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.bpj.2008.12.3952","article-title":"Mechanism and energetics of charybdotoxin unbinding from a potassium channel from molecular dynamics simulations","volume":"96","author":"Chen","year":"2009","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbrc.2020.08.050_bib26","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1021\/bi026400b","article-title":"Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3","volume":"41","author":"Lanigan","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2020.08.050_bib27","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1074\/jbc.M112.433888","article-title":"Two conserved arginine residues from the SK3 potassium channel outer vestibule control selectivity of recognition by scorpion toxins","volume":"288","author":"Feng","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.08.050_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084903","article-title":"hERG potassium channel blockage by scorpion toxin BmKKx2 enhances erythroid differentiation of human leukemia cells K562","volume":"8","author":"Ma","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.08.050_bib29","doi-asserted-by":"crossref","first-page":"15487","DOI":"10.1074\/jbc.M115.639500","article-title":"Kv channel S1-S2 linker working as a binding site of human beta-defensin 2 for channel activation modulation","volume":"290","author":"Feng","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.08.050_bib30","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1096\/fj.15-274787","article-title":"Human alpha-defensins are immune-related Kv1.3 channel inhibitors: new support for their roles in adaptive immunity","volume":"29","author":"Xie","year":"2015","journal-title":"Faseb. J."},{"key":"10.1016\/j.bbrc.2020.08.050_bib31","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.290.14.1875","article-title":"Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial","volume":"290","author":"Harris","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.bbrc.2020.08.050_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1468-3083.2008.02855.x","article-title":"Psoriatic plaque erosion: a rare side effect of methotrexate","volume":"23","author":"Bilac","year":"2009","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.rhu.0000250298.57783.b5","article-title":"Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor?","volume":"12","author":"Houtman","year":"2006","journal-title":"J.\u00a0Clin. Rheumatol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/PL00011213","article-title":"Eosinophilia as a side-effect of methotrexate in patients with chronic arthritis","volume":"20","author":"Savolainen","year":"2001","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF02231787","article-title":"Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis","volume":"12","author":"Bolla","year":"1993","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/1535-7163.MCT-08-0759","article-title":"Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells","volume":"8","author":"Morales","year":"2009","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.bbrc.2020.08.050_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bcp.2005.10.048","article-title":"Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide","volume":"71","author":"Lindgren","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib38","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1038\/sj.onc.1208834","article-title":"Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells","volume":"24","author":"Morales","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.08.050_bib39","first-page":"139","article-title":"Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines","volume":"9","author":"McGuire","year":"1997","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bbrc.2020.08.050_bib40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1634\/theoncologist.1-4-244","article-title":"Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era","volume":"1","author":"Schilsky","year":"1996","journal-title":"Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.bbrc.2020.08.050_bib41","article-title":"New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells","volume":"25","author":"Neradil","year":"2012","journal-title":"Klin. Onkol."},{"key":"10.1016\/j.bbrc.2020.08.050_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/0008-5472.CAN-16-2372","article-title":"Kv1.3 channels mark functionally competent CD8+ tumor-infiltrating lymphocytes in head and neck cancer","volume":"77","author":"Chimote","year":"2017","journal-title":"Can. Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2031651X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2031651X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:57:13Z","timestamp":1757764633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2031651X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0006291X2031651X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.08.050","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate, a small molecular scaffold targeting Kv1.3 channel extracellular pore region","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.08.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}